Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies.
Mundi PS, Dela Cruz FS, Grunn A, Diolaiti D, Mauguen A, Rainey AR, Guillan K, Siddiquee A, You D, Realubit R, Karan C, Ortiz MV, Douglass EF, Accordino M, Mistretta S, Brogan F, Bruce JN, Caescu CI, Carvajal RD, Crew KD, Decastro G, Heaney M, Henick BS, Hershman DL, Hou JY, Iwamoto FM, Jurcic JG, Kiran RP, Kluger MD, Kreisl T, Lamanna N, Lassman AB, Lim EA, Manji GA, McKhann GM, McKiernan JM, Neugut AI, Olive KP, Rosenblat T, Schwartz GK, Shu CA, Sisti MB, Tergas A, Vattakalam RM, Welch M, Wenske S, Wright JD, Canoll P, Hibshoosh H, Kalinsky K, Aburi M, Sims PA, Alvarez MJ, Kung AL, Califano A. Mundi PS, et al. Cancer Discov. 2023 Jun 2;13(6):1386-1407. doi: 10.1158/2159-8290.CD-22-1020. Cancer Discov. 2023. PMID: 37061969 Free PMC article.
Validation of a non-oncogene encoded vulnerability to exportin 1 inhibition in pediatric renal tumors.
Coutinho DF, Mundi PS, Marks LJ, Burke C, Ortiz MV, Diolaiti D, Bird L, Vallance KL, Ibáñez G, You D, Long M, Rosales N, Grunn A, Ndengu A, Siddiquee A, Gaviria ES, Rainey AR, Fazlollahi L, Hosoi H, Califano A, Kung AL, Dela Cruz FS. Coutinho DF, et al. Among authors: mundi ps. Med. 2022 Nov 11;3(11):774-791.e7. doi: 10.1016/j.medj.2022.09.002. Epub 2022 Oct 3. Med. 2022. PMID: 36195086 Free PMC article.
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer.
Kearney M, Franks L, Lee S, Tiersten A, Makower DF, Cigler T, Mundi P, Chi DC, Goel A, Klein P, Andreopoulou E, Sparano J, Trivedi M, Accordino M, Califano A, Hershman DL, Silva J, Kalinsky K. Kearney M, et al. Breast Cancer Res Treat. 2021 Aug;189(1):177-185. doi: 10.1007/s10549-021-06306-4. Epub 2021 Jun 24. Breast Cancer Res Treat. 2021. PMID: 34169393 Free PMC article. Clinical Trial.
Reply to 'H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines'.
Alvarez MJ, Yan P, Alpaugh ML, Bowden M, Sicinska E, Zhou CW, Karan C, Realubit RB, Mundi PS, Grunn A, Jäger D, Chabot JA, Fojo AT, Oberstein PE, Hibshoosh H, Milsom JW, Kulke MH, Loda M, Chiosis G, Reidy-Lagunes DL, Califano A. Alvarez MJ, et al. Among authors: mundi ps. Nat Genet. 2019 Oct;51(10):1427-1428. doi: 10.1038/s41588-019-0509-5. Nat Genet. 2019. PMID: 31548719 Free PMC article. No abstract available.
Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trial.
Kalinsky K, Sparano JA, Zhong X, Andreopoulou E, Taback B, Wiechmann L, Feldman SM, Ananthakrishnan P, Ahmad A, Cremers S, Sireci AN, Cross JR, Marks DK, Mundi P, Connolly E, Crew KD, Maurer MA, Hibshoosh H, Lee S, Hershman DL. Kalinsky K, et al. Clin Transl Oncol. 2018 Nov;20(11):1474-1483. doi: 10.1007/s12094-018-1888-2. Epub 2018 May 7. Clin Transl Oncol. 2018. PMID: 29736694 Free PMC article. Clinical Trial.
Intermittent MEK inhibition for the treatment of metastatic uveal melanoma.
Khan S, Patel SP, Shoushtari AN, Ambrosini G, Cremers S, Lee S, Franks L, Singh-Kandah S, Hernandez S, Sender N, Vuolo K, Nesson A, Mundi P, Izar B, Schwartz GK, Carvajal RD. Khan S, et al. Front Oncol. 2022 Sep 29;12:975643. doi: 10.3389/fonc.2022.975643. eCollection 2022. Front Oncol. 2022. PMID: 36249046 Free PMC article.
Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state.
Echeverria GV, Ge Z, Seth S, Zhang X, Jeter-Jones S, Zhou X, Cai S, Tu Y, McCoy A, Peoples M, Sun Y, Qiu H, Chang Q, Bristow C, Carugo A, Shao J, Ma X, Harris A, Mundi P, Lau R, Ramamoorthy V, Wu Y, Alvarez MJ, Califano A, Moulder SL, Symmans WF, Marszalek JR, Heffernan TP, Chang JT, Piwnica-Worms H. Echeverria GV, et al. Sci Transl Med. 2019 Apr 17;11(488):eaav0936. doi: 10.1126/scitranslmed.aav0936. Sci Transl Med. 2019. PMID: 30996079 Free PMC article.
25 results